OncoCyte Corp Company Insiders
| OCX Stock | USD 2.44 0.09 3.56% |
OncoCyte Corp's insiders are aggressively buying. The analysis of the overall insider sentiment regarding OncoCyte Corp suggests that vertually all insiders are extremely bullish. OncoCyte Corp employs about 43 people. The company is managed by 24 executives with a total tenure of roughly 66 years, averaging almost 2.0 years of service per executive, having 1.79 employees per reported executive.
OncoCyte Corp's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-10-02 | Broadwood Partners, L.P. | Acquired 1315339 @ 2.95 | View | ||
| 2024-04-11 | Josh Riggs | Acquired 3390 @ 2.95 | View |
Monitoring OncoCyte Corp's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
OncoCyte |
OncoCyte Corp's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with OncoCyte Corp's future performance. Based on our forecasts, it is anticipated that OncoCyte will maintain a workforce of slightly above 40 employees by December 2024.OncoCyte Corp Management Team Effectiveness
The company has Return on Asset of (0.1884) % which means that on every $100 spent on assets, it lost $0.1884. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.6532) %, meaning that it generated no profit with money invested by stockholders. OncoCyte Corp's management efficiency ratios could be used to measure how well OncoCyte Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.59 in 2024. Return On Capital Employed is likely to drop to -0.39 in 2024. At this time, OncoCyte Corp's Other Current Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 15.7 M in 2024, whereas Total Assets are likely to drop slightly above 49.1 M in 2024.Common Stock Shares Outstanding is likely to rise to about 8 M in 2024, despite the fact that Net Loss is likely to grow to (62.8 M).
OncoCyte Corp Workforce Comparison
OncoCyte Corp is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 8,701. OncoCyte Corp adds roughly 43.0 in number of employees claiming only tiny portion of equities under Health Care industry.
OncoCyte Corp Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OncoCyte Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on OncoCyte Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, OncoCyte Corp insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 9.0 | 9 | 1 | 2,877,288 | 0.00 |
| 2023-12-01 | 0.5 | 1 | 2 | 8,482 | 277,987 |
| 2023-06-01 | 6.0 | 18 | 3 | 31,180,306 | 6,650,363 |
| 2023-03-01 | 1.6667 | 5 | 3 | 802,823 | 8,221,186 |
| 2022-12-01 | 0.4286 | 6 | 14 | 863,797 | 1,647,710 |
| 2022-09-01 | 21.0 | 21 | 1 | 1,263,000 | 1,176 |
| 2022-06-01 | 3.4545 | 38 | 11 | 30,480,576 | 327,531 |
| 2021-09-01 | 0.8 | 4 | 5 | 638,461 | 137,834 |
| 2021-06-01 | 3.4 | 17 | 5 | 630,207 | 181,714 |
| 2020-12-01 | 4.25 | 17 | 4 | 331,915 | 43,700 |
| 2020-06-01 | 10.0 | 10 | 1 | 1,528,221 | 20,000 |
| 2020-03-01 | 3.5 | 14 | 4 | 2,386,898 | 2,660,006 |
| 2019-09-01 | 3.5 | 14 | 4 | 3,270,000 | 6,570,000 |
| 2018-09-01 | 19.0 | 19 | 1 | 504,476 | 250,000 |
| 2018-06-01 | 7.0 | 7 | 1 | 725,000 | 20,000 |
| 2017-09-01 | 2.0 | 2 | 1 | 0.00 | 0.00 |
| 2017-03-01 | 5.0 | 5 | 1 | 306,900 | 0.00 |
| 2016-12-01 | 0.5 | 1 | 2 | 230,769 | 150,000 |
| 2016-09-01 | 0.6667 | 2 | 3 | 40,000 | 1,538,462 |
OncoCyte Corp Notable Stakeholders
An OncoCyte Corp stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as OncoCyte Corp often face trade-offs trying to please all of them. OncoCyte Corp's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting OncoCyte Corp's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael West | Director, CEO of Biotime Inc and President of Biotime Inc | Profile | |
| Ronald Andrews | President, Chief Executive Officer, Director | Profile | |
| Mitchell Levine | Chief Financial Officer | Profile | |
| Albert Parker | Chief Operating Officer | Profile | |
| James Liu | Controller, Director | Profile | |
| Peter Hong | General VP | Profile | |
| Andrea James | Chief Officer | Profile | |
| Ekkehard MD | Chief Officer | Profile | |
| Joshua Riggs | Interim Officer | Profile | |
| Tony Kalajian | Senior Vice President Chief Accounting Officer | Profile | |
| Andrew Last | Independent Director | Profile | |
| YuhMin Chiang | Senior Development | Profile | |
| Douglas Ross | Chief Medical Officer | Profile | |
| Melinda Griffith | Independent Director | Profile | |
| Anish John | Chief Officer | Profile | |
| William Annett | Advisor | Profile | |
| Andrew Arno | Independent Director | Profile | |
| Gisela Paulsen | COO Pres | Profile | |
| Sara Riordan | Director Education | Profile | |
| Lyndal Hesterberg | Chief Scientific Officer | Profile | |
| Cavan Redmond | Independent Chairman of the Board | Profile | |
| Padma Sundar | Senior Vice President - Marketing and Market Access | Profile | |
| Robert Seitz | Head Oncology | Profile | |
| Sandra ODonald | Senior Operations | Profile |
About OncoCyte Corp Management Performance
The success or failure of an entity such as OncoCyte Corp often depends on how effective the management is. OncoCyte Corp management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of OncoCyte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the OncoCyte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.52) | (1.59) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (1.09) | (1.14) |
Please note, the imprecision that can be found in OncoCyte Corp's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of OncoCyte Corp. Check OncoCyte Corp's Beneish M Score to see the likelihood of OncoCyte Corp's management manipulating its earnings.
OncoCyte Corp Workforce Analysis
Traditionally, organizations such as OncoCyte Corp use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare OncoCyte Corp within its industry.OncoCyte Corp Manpower Efficiency
Return on OncoCyte Corp Manpower
| Revenue Per Employee | 35K | |
| Revenue Per Executive | 62.6K | |
| Net Loss Per Employee | 646.1K | |
| Net Loss Per Executive | 1.2M | |
| Working Capital Per Employee | 81.5K | |
| Working Capital Per Executive | 146K |
Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.